trending Market Intelligence /marketintelligence/en/news-insights/trending/f8ZelLBivWfuhdYYQEM0zg2 content esgSubNav
Log in to other products


Looking for more?

Contact Us
In This List

Aptose Biosciences closes common stock offering


Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge


COVID-19 Impact & Recovery: Private Equity

COVID-19 Impact & Recovery: Corporates


COVID-19 Impact & Recovery: Investment Banking

Aptose Biosciences closes common stock offering

Aptose Biosciences Inc. raised about $21.3 million in an offering of its 10 million common shares priced at $1.85 apiece.

The shares sold include the full exercise of the underwriters' option to buy an additional 1.5 million common shares.

Net proceeds will be used to accelerate and expand Aptose's clinical trial programs, along with working capital and general corporate purposes.

RBC Capital Markets and Canaccord Genuity acted as joint book-running managers for the offering, with H.C. Wainwright & Co. and JonesTrading Institutional Services LLC as co-managers.